NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma. Article

Sloan, Andrew E, Gilbert, Mark R, Zhang, Peixin et al. (2018). NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma. . JOURNAL OF CLINICAL ONCOLOGY, 36(15_suppl), 2053-2053. 10.1200/jco.2018.36.15_suppl.2053

cited authors

  • Sloan, Andrew E; Gilbert, Mark R; Zhang, Peixin; Aldape, Kenneth D; Wu, Jing; Rogers, Lisa R; Wen, Patrick Y; Barani, Igor J; Iwamoto, Fabio Massaiti; Raval, Raju R; Voloschin, Alfredo Daniel; De Groot, John Frederick; Won, Minhee; Mehta, Minesh P

authors

publication date

  • May 20, 2018

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3204 Immunology

Digital Object Identifier (DOI)

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • 2053

end page

  • 2053

volume

  • 36

issue

  • 15_suppl